Friday, March 1, 2024
25.1 C
Friday, March 1, 2024
- Advertisement -corhaz 3

Cipla Launches First Batch Of Roche’s Antibody Cocktail In India.

Drug major Roche India on Monday declared the dispatch of its first bunch of antibody cocktail against COVID-19 in India. The antibody cocktail — Casirivimab and Imdevimab – is valued at ₹ 59,750 for each dose. Roche’s antibody cocktail was given to previous US President Donald Trump when he contracted COVID-19 a year ago.

“Each of the 1,200 mg dose of the drug contains 600 mg of Casirivimab and 600 mg of Imdevimab. The price of each dose will be ₹ 59,750. The maximum retail price for the multi-dose pack will be ₹ 1,19,500. Notably, each pack can treat two patients,” said the company in a statement.

The drug will be launched by Cipla in India and the second batch will be available in mid-June.

“The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit two lakh patients as each of the one lakh packs that will be available in India offers treatment for two patients,” said a joint statement by Roche and Cipla.

The drug will be supplied to all major hospitals and Covid care centres.

The Central Drugs Standards Control Organisation (CDSCO) has recently gave an Emergency Use Authorisation (EUA) for this cocktail in India. The cocktail has also received this authorisation in US and several European Union nations.

“Roche is deeply committed to supporting the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalization, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens,” said Managing Director and CEO Managing Director and CEO of Roche Pharma India.

The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen.

More articles

- Advertisement -corhaz 300

Latest article